gene therapy

If a disease is caused by a broken gene, the most direct cure imaginable is to fix the gene itself — to put a working copy into the patient's cells, or to switch off a gene that is doing harm. That is gene therapy: treating disease by changing genes inside the body, rather than just managing symptoms with a drug you take forever.

The hard part is delivery — getting DNA into the right cells, safely. The most common couriers are viruses, stripped of their disease-causing genes and reloaded with a therapeutic gene, since viruses are nature's experts at injecting genetic material into cells; the workhorse today is the adeno-associated virus (AAV). Non-viral methods, such as wrapping DNA or RNA in tiny fat bubbles (lipid nanoparticles), are also used. There are two broad strategies: add a working copy of a missing gene (gene replacement, for recessive diseases where the protein is absent), or silence a gene that is making something toxic. Some therapies are done in vivo, injecting the vector straight into the patient; others are ex vivo, where a patient's own cells are removed, fixed in the lab, and returned.

Gene therapy's history is a hard-won lesson in honesty. Early trials in the late 1990s and 2000s killed patients — one from a runaway immune reaction to the viral vector, others who developed leukemia when the inserted gene landed next to a cancer gene. The field nearly collapsed, then rebuilt itself with safer vectors and now has real, approved cures for blindness, spinal muscular atrophy, and some immune deficiencies. But it remains hard: immune reactions to viral vectors are still a problem, the effect may not last, and these one-time therapies are among the most expensive medicines ever made, costing millions per patient — which makes access, not just science, the central question.